Sunday, November 03, 2019 3:16:55 PM
Posted by Carillo Anthony on November 2, 2019 at 3:10 pm
Myovant Sciences (MYOV) Rating Reaffirmed
In an analyst note sent to investors on Thursday morning, Cowen & Co. maintained their Buy rating on Myovant Sciences (MYOV) shares.
The stock increased 1.65% or $0.09 during the last trading session, reaching $5.55. About 490,299 shares traded. Myovant Sciences Ltd. (MYOV) has declined 63.47% since November 2, 2018 and is downtrending. It has underperformed by 63.47% the S&P500.
Analysts await Myovant Sciences Ltd. (NYSE:MYOV) to report earnings on November, 14. They expect $-0.80 EPS, up 19.19 % or $0.19 from last year’s $-0.99 per share. After $-0.89 actual EPS reported by Myovant Sciences Ltd. for the previous quarter, Wall Street now forecasts -10.11 % EPS growth.
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company has market cap of $497.41 million. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist, for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It currently has negative earnings. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of the hormonal preparation used in assisted reproduction.
More notable recent Myovant Sciences Ltd. (NYSE:MYOV) news were published by: Finance.Yahoo.com which released: “How Much Are Myovant Sciences Ltd. (NYSE:MYOV) Insiders Spending On Buying Shares? – Yahoo Finance” on August 27, 2019, also Benzinga.com with their article: “Stocks That Hit 52-Week Lows On Thursday – Benzinga” published on September 12, 2019, Benzinga.com published: “The Daily Biotech Pulse: PhaseBio Leaps On Trial Results, Pacira Set To Join SmallCap 600 Index, Positive Readout For Amgen’s Blood Cancer Drug – Benzinga” on September 25, 2019. More interesting news about Myovant Sciences Ltd. (NYSE:MYOV) were released by: Benzinga.com and their article: “48 Stocks Moving In Monday’s Mid-Day Session – Benzinga” published on August 19, 2019 as well as Globenewswire.com‘s news article titled: “Myovant Sciences to Present at Upcoming June Investor Conferences – GlobeNewswire” with publication date: June 04, 2019.
https://financerecorder.com/analyst-at-cowen-co-reaffirmed-myovant-sciences-myovstock-rating-as-a-buy/
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM